Th1 cell adjuvant therapy combined with tumor vaccination: A novel strategy for promoting CTL responses while avoiding the accumulation of Tregs

International Immunology

Volumn 19, Issue 2, 2007, Pages 151-161

  Zhang, Yue ^a   Wakita, Daiko ^a   Chamoto, Kenji ^a   Narita, Yoshinori ^a   Matsubara, Naoki ^a   Kitamura, Hidemitsu ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; OVALBUMIN; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; TUMOR VACCINE; CANCER VACCINE; H 2KB PROTEIN, MOUSE; H-2KB PROTEIN, MOUSE; H2 ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HELPER CELL; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPH NODE; MALE; METHODOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; FLOW CYTOMETRY; H-2 ANTIGENS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 33846592824     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl132     Document Type: Article

References (47)

1. Clark, W. R., Walsh, C. M., Glass, A. A., Hayashi, F., Matloubian, M. and Ahmed, R. 1995. Molecular pathways of CTL-mediated cytotoxicity. Immunol. Rev. 146:33.
2. + T-cell-dependent surveillance. Cancer Res. 50:3851.
3. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I. et al. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
4. Melief, C. J., Toes, R. E., Medema, J. P., van der Burg, S. H., Ossendorp, F. and Offringa, R. 2000. Strategies for immunotherapy of cancer. Adv. Immunol. 75:235.
5. Scupoli, M. T., Sartoris, S., Tosi, G. et al. 1996. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 48:301.
6. Bander, N. H., Yao, D., Liu, H. et al. 1997. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33:233.
7. Marchand, M., van Baren, N., Weynants, P. et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
8. Rosenberg, S. A., Yang, J. C. and Restifo, N. P. 2004. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10:909.
9. Ribas, A., Butterfield, L. H., Glaspy, J. A. and Economou, J. S. 2003. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21:2415.
10. Coulie, P. G. and van der Bruggen, P. 2003. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 15:131.
11. + T cells. Eur. J. Immunol. 32:374.
12. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J. Immunol. 164:3902.
13. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165:6047.
14. + T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:88.
15. Sun, J. C. and Bevan, M. J. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339.
16. + T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. 62:6438.
17. Nishimura, T., Iwakabe, K., Sekimoto, M. et al. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:617.
18. Chamoto, K., Wakita, D., Narita, Y. et al. 2006. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class IInegative tumor tissue by T-helper type 1 cell therapy. Cancer Res. 66:1809.
19. Ikeda, H., Chamoto, K., Tsuji, T. et al. 2004. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 95:697.
20. Wakita, D., Chamoto, K., Zhang, Y. et al. 2006. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int. Immunol. 18: 425.
21. Suzuki, Y., Wakita, D., Chamoto, K. et al. 2004. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64:8754.
22. Chamoto, K., Tsuji, T., Funamoto, A. et al. 2004. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 64:386.
23. Rennert, P. D., Hochman, P. S., Flavell, R. A. et al. 2001. Essential role of lymph nodes in contact hypersensitivity revealed in lymphotoxin-alpha-deficient mice. J. Exp. Med. 193:1227.
24. Miller, M. J., Wei, S. H., Parker, I. and Cahalan, M. D. 2002. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 296:1869.
25. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 4:579.
26. Mempel, T. R., Henrickson, S. E. and Von Andrian, U. H. 2004. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154.
27. Barnden, M. J., Allison, J., Heath, W. R. and Carbone, F. R. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based a- and h-chain genes under the control of heterologous regulatory elements. Immunol. Cell. Biol. 6:34.
28. Nishimura, T., Burakoff, S. J. and Herrmann, S. H. 1987. Protein kinase C required for cytotoxic T lymphocyte triggering. J. Immunol. 139:2888.
29. Hontsu, S., Yoneyama, H., Ueha, S. et al. 2004. Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice. Int. Immunopharmacol. 4:1785.
30. Curiel, T. J., Coukos, G., Zou, L. et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942
31. Berthier-Vergnes, O., Bermond, F., Flacher, V., Massacrier, C., Schmitt, D. and Peguet-Navarro, J. 2005. TNF-alpha enhances phenotypic and functional maturation of human epidermal Langerhans cells and induces IL-12 p40 and IP-10/CXCL-10 production. FEBS Lett. 579:3660.
32. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409.
33. +CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173:1444.
34. Grande, C., Firvida, J. L., Navas, V. and Casal, J. 2006. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17:1.
35. Rosenberg, S. A., Yang, J. C., Topalian, S. L. et al. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907.
36. Nicholl, M., Lodge, A., Brown, I., Sugg, S. L. and Shilyansky, J. 2004. Restored immune response to an MHC-II-restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. J. Pediatr. Surg. 39:941.
37. Gajewski, T. F., Meng, Y. and Harlin, H. 2006. Immune suppression in the tumor microenvironment. J. Immunother. 29:233.
38. Wang, D. and Dubois, R. N. 2006. Prostaglandins and cancer. Gut 55:115.
39. Sakaguchi, S. 2000. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 101:455.
40. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 28:120.
41. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:4766.
42. Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H. and Fujii, H. 2003. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9:4404.
43. Liyanage, U. K., Moore, T. T., Joo, H. G. et al. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169:2756.
44. Mukherji, B., Guha, A., Chakraborty, N. G. et al. 1989. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J. Exp. Med. 169:1961.
45. Chakraborty, N. G., Twardzik, D. R., Sivanandham, M., Ergin, M. T., Hellstrom, K. E. and Mukherji, B. 1990. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J. Immunol. 145:2359.
46. +CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409.
47. Okano, F., Merad, M., Furumoto, K. and Engleman, E. G. 2005. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. J. Immunol. 174:2645.